P6P2 Stock Overview
A regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
RepliCel Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0005 |
| 52 Week High | US$0.088 |
| 52 Week Low | US$0.0005 |
| Beta | 0.95 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -95.24% |
| 33 Year Change | -99.74% |
| 5 Year Change | -99.67% |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| P6P2 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -92.3% | 2.2% | 0.2% |
| 1Y | -95.2% | 3.6% | 8.5% |
Return vs Industry: P6P2 underperformed the German Life Sciences industry which returned 3.6% over the past year.
Return vs Market: P6P2 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| P6P2 volatility | |
|---|---|
| P6P2 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: P6P2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine P6P2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Andrew Schutte | www.replicel.com |
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company’s product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration.
RepliCel Life Sciences Inc. Fundamentals Summary
| P6P2 fundamental statistics | |
|---|---|
| Market cap | €12.48k |
| Earnings (TTM) | €524.26k |
| Revenue (TTM) | €243.03k |
0.0x
P/E Ratio0.1x
P/S RatioIs P6P2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P6P2 income statement (TTM) | |
|---|---|
| Revenue | CA$353.74k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$353.74k |
| Other Expenses | -CA$409.34k |
| Earnings | CA$763.08k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.012 |
| Gross Margin | 100.00% |
| Net Profit Margin | 215.72% |
| Debt/Equity Ratio | -25.0% |
How did P6P2 perform over the long term?
See historical performance and comparison